Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

BMS Partners with Tigerlily Foundation to Address Racial Disparities in Breast Cancer Clinical Trial Access – Pharma Giant Commits to Improving Representation of Young Women of Color

Fineline Cube May 18, 2026
Company Deals

Allogene Therapeutics Terminates Asian CAR-T Joint Venture with Overland Pharmaceuticals – Strategic Retreat from Allogeneic Cell Therapy Market in Asia

Fineline Cube May 18, 2026
Company Deals

Eli Lilly Commits $50M to UNICEF USA Alliance Targeting Non-Communicable Disease Prevention in Children Across 21 LMICs

Fineline Cube May 15, 2026
Company Deals

TenNor Therapeutics Raises $71M in Hong Kong IPO – Antimicrobial Pipeline Targets H. pylori and Implant-Associated Infections

Fineline Cube May 14, 2026
Company Deals Drug

Fosun Pharma Secures Global Rights to AriBio’s Alzheimer’s Drug AR1001 in $240M Deal – PDE-5 Inhibitor Shows Promise in Phase III

Fineline Cube May 14, 2026
Policy / Regulatory

China Issues National Guidelines for Home Hospital Bed Services to Address Healthcare Access for Vulnerable Populations

Fineline Cube May 15, 2026
Company Drug

Regeneron’s Fianlimab-Cemiplimab Combination Fails to Meet Primary Endpoint in Phase III Melanoma Trial – LAG-3/PD-1 Dual Therapy Shows No PFS Benefit Over Pembrolizumab Monotherapy

Fineline Cube May 18, 2026
Company Drug

AstraZeneca’s Baxfendy Secures FDA Approval for Uncontrolled Hypertension – First-in-Class Aldosterone Synthase Inhibitor with Selective CYP11B2 Targeting

Fineline Cube May 18, 2026
Company Medical Device

Jiangsu BioPerfectus’ Dengue Detection Kit Gains NMPA Approval for Commercialization

Fineline Cube May 11, 2024

Jiangsu BioPerfectus Technologies Co., Ltd (SHA: 688399), a leading in vitro diagnostic (IVD) product manufacturer...

Company Deals

DSciLab, mRNA Pharma Startup, Bags RMB 100 Million in Angel Financing Led by Fosun Health

Fineline Cube May 11, 2024

DSciLab Co., Ltd, a China-based mRNA pharmaceutical company nurtured by Fosun Health Capital, has announced...

Company Deals

Novo Nordisk Partners with Flagship Pioneering for Development of Novel Obesity Treatments

Fineline Cube May 11, 2024

Denmark-based pharmaceutical giant Novo Nordisk (CPH: NOVO-B) has announced a partnership with life sciences venture...

Company

Viatris Q1 2024 Results Show Slight Dip in Base Business Brands Amid Overall Stabilization

Fineline Cube May 11, 2024

US pharmaceutical company Viatris (NASDAQ: VTRS) has reported its financial results for the first quarter...

Company Deals

Sanofi Secures Novavax Vaccine Tech in a Deal Valued at Up to USD 1.2 Billion

Fineline Cube May 11, 2024

France’s Sanofi (NASDAQ: SNY) has announced a strategic partnership with protein-based vaccines specialist Novavax (NASDAQ:...

Policy / Regulatory

China Unveils Sweeping 2024 Legislative Plan with Healthcare and Pharma at Forefront

Fineline Cube May 11, 2024

The State Council of China has released its annual legislative work plan for 2024, outlining...

Company Drug

MSD’s Keytruda Adjuvant Treatment for High-Risk Endometrial Cancer Fails to Meet Primary Endpoint

Fineline Cube May 10, 2024

Merck, Sharp & Dohme (MSD; NYSE: MRK) has announced that a late-stage trial for its...

Company

Takeda’s Fiscal 2023 Revenues Grow 1.5%, CEO Weber Forecasts 2025 Profitability After 2024 Dip

Fineline Cube May 10, 2024

Takeda’s (TYO: 4502) annual report for the fiscal year ended March 31, 2024, has been...

Company Drug

WestGene Biopharma’s Groundbreaking mRNA Vaccine for EB Virus Tumors Gets FDA Green Light

Fineline Cube May 10, 2024

WestGene Biopharma Co., Ltd., a biopharmaceutical company based in Chengdu, has announced that its drug...

Company Drug

RJK Biopharma’s RJK002 Earns Tacit Approval for Amyotrophic Lateral Sclerosis Clinical Trial

Fineline Cube May 10, 2024

Shanghai-based RJK Biopharma Ltd. has announced that its Category 1 drug RJK002 has received tacit...

Company Deals Drug

BioNTech Secures Global Rights to Biotheus Inc.’s Pre-Clinical Bispecific Antibody

Fineline Cube May 10, 2024

Biotheus Inc., a biopharmaceutical company based in China, has announced that its German partner BioNTech...

Company Drug

China Grants Marketing Nod to Ferring Pharmaceuticals’ Rekovelle for Assisted Reproduction

Fineline Cube May 10, 2024

Switzerland-based Ferring Pharmaceuticals Ltd announced that its recombinant human follicle stimulating hormone δ injection, Rekovelle,...

Policy / Regulatory

Hong Kong SAR and NMPA Renew Agreements to Boost Drug and Medical Device Regulation

Fineline Cube May 10, 2024

Professor Chung-mau LO, BBS, JP, Secretary for Health of the Hong Kong Special Administrative Region...

Company Drug

Chia Tai Tianqing’s PD-L1 Antibody Benmelstobart Wins NMPA Nod for ES-SCLC

Fineline Cube May 10, 2024

China-based Chia Tai Tianqing has announced that it has received marketing approval from the National...

Company

GSK Shakes Up Leadership with Promotion of Cecilia Qi and Appointment of Sherman Yu

Fineline Cube May 10, 2024

Mike Crichton, Senior Vice President of GlaxoSmithKline (GSK, NYSE: GSK) for the Greater China and...

Company Drug

Sichuan Biokin Pharmaceutical Advances BL-B16D1 to Clinical Trial for Advanced Solid Tumors

Fineline Cube May 10, 2024

Sichuan Biokin Pharmaceutical Co., Ltd (SHA: 688506), a pharmaceutical company based in China, has announced...

Company Drug

Bio-Thera Solutions’ PD-1 and ADC Combo Gets NMPA Approval for Clinical Trial in Solid Tumors

Fineline Cube May 10, 2024

Bio-Thera Solutions, Ltd (SHA: 688177), a biopharmaceutical company based in China, has announced that it...

Company Drug

Sandoz Q1 2024 Results Highlight 6% Growth, Led by Biosimilars and European Strength

Fineline Cube May 10, 2024

Switzerland-based Sandoz (SWX: SDZ) has reported its financial results for the first quarter of 2024,...

Company Drug

Jiangsu QYuns Therapeutics Gets NMPA Green Light for CSU Treatment QX013N

Fineline Cube May 10, 2024

Jiangsu QYuns Therapeutics Co., Ltd (HKG: 2509), a biopharmaceutical company based in China, has announced...

Company Medical Device

MicroPort MedBot’s Toumai Robot Gets EU Green Light for Broad Surgical Applications

Fineline Cube May 10, 2024

Shanghai MicroPort MedBot (Group) Co., Ltd (HKG: 2252) has announced that its Toumai endoscopic surgery...

Posts pagination

1 … 364 365 366 … 667

Recent updates

  • BMS Partners with Tigerlily Foundation to Address Racial Disparities in Breast Cancer Clinical Trial Access – Pharma Giant Commits to Improving Representation of Young Women of Color
  • Regeneron’s Fianlimab-Cemiplimab Combination Fails to Meet Primary Endpoint in Phase III Melanoma Trial – LAG-3/PD-1 Dual Therapy Shows No PFS Benefit Over Pembrolizumab Monotherapy
  • AstraZeneca’s Baxfendy Secures FDA Approval for Uncontrolled Hypertension – First-in-Class Aldosterone Synthase Inhibitor with Selective CYP11B2 Targeting
  • Harbour BioMed Unveils Preclinical Data for LET003 – AI-Discovered ACVR2A/2B Antibody Shows Best-in-Class Potential in Obesity Combination Therapy with GLP-1 Drugs
  • Allogene Therapeutics Terminates Asian CAR-T Joint Venture with Overland Pharmaceuticals – Strategic Retreat from Allogeneic Cell Therapy Market in Asia
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

BMS Partners with Tigerlily Foundation to Address Racial Disparities in Breast Cancer Clinical Trial Access – Pharma Giant Commits to Improving Representation of Young Women of Color

Company Drug

Regeneron’s Fianlimab-Cemiplimab Combination Fails to Meet Primary Endpoint in Phase III Melanoma Trial – LAG-3/PD-1 Dual Therapy Shows No PFS Benefit Over Pembrolizumab Monotherapy

Company Drug

AstraZeneca’s Baxfendy Secures FDA Approval for Uncontrolled Hypertension – First-in-Class Aldosterone Synthase Inhibitor with Selective CYP11B2 Targeting

Company Drug

Harbour BioMed Unveils Preclinical Data for LET003 – AI-Discovered ACVR2A/2B Antibody Shows Best-in-Class Potential in Obesity Combination Therapy with GLP-1 Drugs

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.